Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-CD27/TNFRSF7 Antibody-FITC (3U92) is a FITC-conjugated Mouse antibody targeting CD27/TNFRSF7. Anti-CD27/TNFRSF7 Antibody-FITC (3U92) can be used in FCM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 T | $35 | 7-10 days | 7-10 days | |
| 100 T | $81 | 7-10 days | 7-10 days |
| Description | Anti-CD27/TNFRSF7 Antibody-FITC (3U92) is a FITC-conjugated Mouse antibody targeting CD27/TNFRSF7. Anti-CD27/TNFRSF7 Antibody-FITC (3U92) can be used in FCM. |
| Synonyms | Tp55, Tnfrsf7, S152, CD27 molecule |
| Ig Type | Mouse IgG1 |
| Clone | 3U92 |
| Reactivity | Human |
| Specificity | Human CD27/TNFRSF7 |
| Verified Activity | Flow cytometric analysis of anti-human CD27 on human whole blood lymphocytes. Human lymphocytes were stained with FITC-anti human CD27 (solid line) or FITC-Mouse IgG isotype control (dashed line). |
| Application | |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD27 / TNFRSF7 (rh CD27 / TNFRSF7; NP_001233.1Met 1-Ile 192) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | CD27, also known as TNFRSF7, is a member of the TNF-receptor superfamily limited to cells of the lymphoid lineage, and exists as both a dimeric glycoprotein on the cell surface and as a soluble protein in serum. As a type I transmembrane glycoprotein of about 55 kDa existing as disulfide-linked homodimer, CD27 has been shown to play roles in lymphoid proliferation, differentiation, and apoptosis.It has an important role in the generation of T cell immunity and is an robust marker for normal memory B cells. It is a T and B cell co-stimulatory molecule, the activity of CD27 is governed by its TNF-like ligand CD70 on lymphocytes and dendritic cells. The CD27-CD70 interaction is required for Th1 generation responses to differentiation signals and long-term maintenance of T cell immunity, and meanwhile, plays a key role in regulating B-cell differentiation, activation and immunoglobulin synthesis.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | FITC |
| Others Formats | Unconjugated/APC/PerCP/PE |
| Antibody Types Available | 5 |
| Immunogen | Recombinant Protein: Human CD27 / TNFRSF7 protein |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.